ATE320427T1 - Substituierte pyrazole - Google Patents

Substituierte pyrazole

Info

Publication number: ATE320427T1
Authority: AT; Austria
Prior art keywords: substituted pyrazoles; methods; pyrazoles; substituted; cathepsin
Prior art date: 2000-08-14

Application number

AT01965898T

Other languages

English (en)

Inventor

Christopher R Butler

Hui Cai

James P Edwards

Cheryl A Grice

Darin J Gustin

Haripada Khatuya

Steven P Meduna

Barbara A Pio

Clark A Sehon

Kevin L Tays

Jianmei Wei

Original Assignee

Ortho Mcneil Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-14

Filing date

2001-08-10

Publication date

2006-04-15

2001-08-10 Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc

2006-04-15 Application granted granted Critical

2006-04-15 Publication of ATE320427T1 publication Critical patent/ATE320427T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

AT01965898T 2000-08-14 2001-08-10 Substituierte pyrazole ATE320427T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22517800P	2000-08-14	2000-08-14
US09/927,324 US6953793B2 (en)	2000-08-14	2001-08-10	Substituted pyrazoles

Publications (1)

Publication Number	Publication Date
ATE320427T1 true ATE320427T1 (de)	2006-04-15

Family

ID=26919364

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01965898T ATE320427T1 (de)	2000-08-14	2001-08-10	Substituierte pyrazole

Country Status (19)

Country	Link
US (2)	US6953793B2 (de)
EP (1)	EP1309593B1 (de)
JP (1)	JP5049447B2 (de)
KR (1)	KR100837193B1 (de)
AT (1)	ATE320427T1 (de)
AU (2)	AU8645401A (de)
BR (1)	BRPI0113286B8 (de)
CA (1)	CA2419552C (de)
CZ (1)	CZ307185B6 (de)
DE (1)	DE60118004T2 (de)
DK (1)	DK1309593T3 (de)
ES (1)	ES2261463T3 (de)
HU (1)	HU230538B1 (de)
MX (1)	MXPA03001422A (de)
NZ (1)	NZ524191A (de)
PL (1)	PL213103B1 (de)
PT (1)	PT1309593E (de)
RU (1)	RU2317988C2 (de)
WO (1)	WO2002014315A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6566372B1 (en)	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
JP5049447B2 (ja) *	2000-08-14	2012-10-17	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	置換ピラゾール
US7589202B2 (en) *	2000-08-14	2009-09-15	Ortho Mcneil Pharmaceutical, Inc.	Substituted pyrazoles
US20050101587A9 (en) *	2000-08-14	2005-05-12	Butler Christopher R.	Method for treating allergies using substituted pyrazoles
JP2004523506A (ja) *	2000-12-22	2004-08-05	アクシス・ファーマシューティカルズ・インコーポレイテッド	カテプシン阻害剤としての新規な化合物と組成物
RU2268883C2 (ru) *	2001-04-18	2006-01-27	Эро-Селтик, С.А.	Аналоги ноницептина и фармацевтическая композиция на их основе
PT1379246E (pt) *	2001-04-18	2009-01-14	Euro Celtique Sa	Análogos de nociceptina
US20040147503A1 (en) *	2002-06-04	2004-07-29	Sheila Zipfeil	Novel compounds and compositions as cathepsin inhibitors
PL408347A1 (pl)	2002-09-24	2014-08-18	Novartis Ag	Kombinacja, zastosowanie kombinacji oraz zastosowanie agonisty receptora S1P
US7384970B2 (en)	2003-03-24	2008-06-10	Irm Llc	Inhibitors of cathepsin S
US7109243B2 (en)	2003-03-24	2006-09-19	Irm Llc	Inhibitors of cathepsin S
US7173051B2 (en)	2003-06-13	2007-02-06	Irm, Llc	Inhibitors of cathepsin S
US7256207B2 (en)	2003-08-20	2007-08-14	Irm Llc	Inhibitors of cathepsin S
FR2885904B1 (fr) *	2005-05-19	2007-07-06	Aventis Pharma Sa	Nouveaux derives du fluorene, compositions les contenant et utilisation
EP1906965B1 (de) *	2005-06-22	2015-05-06	ChemoCentryx, Inc.	Azaindazol-verbindungen und anwendungsverfahren
TW200813018A (en)	2006-06-09	2008-03-16	Astrazeneca Ab	Novel compounds
CL2007003590A1 (es) *	2006-12-12	2008-02-29	Wyeth Corp	Compuestos derivados de aril sulfamida; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en prevencion y tratamiento de sintomas vasomotrices, disfuncion sexual, transtornos gastrointestinales, transt
US20090118274A1 (en) *	2007-02-15	2009-05-07	Darin Allen	Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080207683A1 (en) *	2007-02-15	2008-08-28	Darin Allen	Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090099157A1 (en) *	2007-02-15	2009-04-16	Ameriks Michael K	Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s
US20080269241A1 (en) *	2007-02-15	2008-10-30	Darin Allen	Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080200454A1 (en) *	2007-02-15	2008-08-21	Ameriks Michael K	Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US8119661B2 (en)	2007-09-11	2012-02-21	Astrazeneca Ab	Piperidine derivatives and their use as muscarinic receptor modulators
CA2728514C (en)	2008-06-20	2020-08-11	Novartis Ag	Paediatric compositions for treating multiple sclerosis
US9643922B2 (en)	2008-08-18	2017-05-09	Yale University	MIF modulators
AU2009283195A1 (en) *	2008-08-18	2010-02-25	Yale University	MIF modulators
US9540322B2 (en)	2008-08-18	2017-01-10	Yale University	MIF modulators
TWI475020B (zh) *	2009-03-12	2015-03-01		The substituted nicotine amide as a KCNQ2 / 3 modifier
AU2010282506A1 (en) *	2009-08-12	2012-03-08	Janssen Pharmaceutica Nv	Process for the preparation of Cathepsin S inhibitors
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
HRP20170430T1 (hr)	2012-06-13	2017-06-16	Incyte Holdings Corporation	Supstituirani triciklični spojevi kao inhibitori fgfr
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
RU2674249C2 (ru)	2012-11-05	2018-12-06	НэнтБайо, Инк.	Замещенные производные индол-5-ола и их терапевтическое применение
WO2014078257A1 (en)	2012-11-14	2014-05-22	Glaxosmithkline Llc	Thieno[3,2-c]pyridin-4(5h)-ones as bet inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
JP2016514703A (ja)	2013-03-15	2016-05-23	ナントバイオサイエンス、インコーポレイテッド	置換インドール−５−オール誘導体及びそれらの治療適用
PL2986610T4 (pl)	2013-04-19	2019-06-28	Incyte Holdings Corporation	Bicykliczne heterocykle jako inhibitory FGFR
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
JP6654636B2 (ja) *	2014-12-02	2020-02-26	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	新規ピペリジン誘導体
MY197720A (en)	2015-02-20	2023-07-10	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3319968A1 (de)	2015-07-06	2018-05-16	Rodin Therapeutics, Inc.	Heterobicyclische n-aminophenyl-amide als inhibitoren der histondeacetylase
SMT202100702T1 (it)	2015-07-06	2022-01-10	Alkermes Inc	Inibitori etero-alo dell'istone deacetilasi
US9951069B1 (en)	2017-01-11	2018-04-24	Rodin Therapeutics, Inc.	Bicyclic inhibitors of histone deacetylase
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
DK3664802T3 (en)	2017-08-07	2022-05-30	Alkermes Inc	Bicyclic inhibitors of histone deacetylase
EP3694322B1 (de)	2017-10-09	2024-07-03	Terumo BCT Biotechnologies, LLC	Lyophilisierungsbehälter und verfahren zu seiner verwendung
BR112020022392A2 (pt)	2018-05-04	2021-02-02	Incyte Corporation	formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
JP7568512B2 (ja)	2018-05-04	2024-10-16	インサイト・コーポレイション	Ｆｇｆｒ阻害剤の塩
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
US11604026B2 (en)	2019-03-14	2023-03-14	Terumo Bct Biotechnologies, Llc	Lyophilization loading tray assembly and system
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
JP7675711B2 (ja)	2019-10-14	2025-05-13	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
PE20221504A1 (es)	2019-12-04	2022-09-30	Incyte Corp	Derivados de un inhibidor de fgfr
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2022221170A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR126102A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr
EP4352060A1 (de)	2021-06-09	2024-04-17	Incyte Corporation	Tricyclische heterocyclen als fgfr-inhibitoren

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US856514A (en) *	1907-03-15	1907-06-11	William T Adams	Cheese-cutter.
US3743409A (en)	1971-06-11	1973-07-03	Xerox Corp	Cutter assembly
JPS5090172A (de)	1973-12-13	1975-07-19
US3994890A (en)	1974-01-31	1976-11-30	Chugai Seiyaku Kabushiki Kaisha	1-Aminoalkyl, 3-phenyl indazoles
JPS5640714B2 (de) *	1974-03-04	1981-09-22
DK27383A (da)	1982-02-17	1983-08-18	Lepetit Spa	Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
JPH0615542B2 (ja)	1986-07-22	1994-03-02	吉富製薬株式会社	ピラゾロピリジン化合物
FR2642759B1 (fr)	1989-02-09	1991-05-17	Laboratorios Esteve Sa	Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante
FR2673628B1 (fr)	1991-03-07	1993-07-09	Esteve Labor Dr	Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
US5264576A (en)	1992-10-22	1993-11-23	Hoechst-Roussel Pharmaceuticals Incorporated	Pyrazolo[4,3-c]pyridines which are intermediates
FR2705962B1 (fr)	1993-06-03	1995-07-13	Rhone Poulenc Agrochimie	Arylpyrazoles fongicides.
KR100228949B1 (ko) *	1993-07-06	1999-11-01	디. 제이. 우드, 스피겔 알렌 제이	이환상 테트라하이드로 피라졸로피리딘
FR2712808B1 (fr)	1993-11-25	1996-02-16	Esteve Labor Dr	Utilisation des dérivés de 1-{4-[4-aryl(ou hétéroaryl)-1-pipérazinyl]-butyl}-1-H-azole pour la préparation de médicaments destinés au traitement des troubles de la sécrétion gastrique .
IL112759A0 (en)	1994-02-25	1995-05-26	Khepri Pharmaceuticals Inc	Novel cysteine protease inhibitors
KR19980703261A (ko)	1995-03-24	1998-10-15	다니엘 이이치. 페트리	가역성 프로테아제 억제제
US5776718A (en)	1995-03-24	1998-07-07	Arris Pharmaceutical Corporation	Reversible protease inhibitors
TW438591B (en)	1995-06-07	2001-06-07	Arris Pharm Corp	Reversible cysteine protease inhibitors
FR2742052B1 (fr)	1995-12-12	1998-04-10	Esteve Labor Dr	Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports
DK0912601T4 (da)	1996-04-22	2009-03-09	Massachusetts Inst Technology	Suppression af immunrespons ved inhibering af cathepsin S
AU7553198A (en)	1997-06-12	1998-12-30	Sumitomo Pharmaceuticals Company, Limited	Pyrazole derivatives
DE69841871D1 (en)	1997-11-05	2010-10-14	Novartis Ag	Dipeptide nitrile
GB9806287D0 (en)	1998-03-24	1998-05-20	Synphar Lab Inc	Monobactam enzyme inhibitors
WO1999058153A1 (en)	1998-05-08	1999-11-18	Brigham & Women's Hospital	Methods of diagnosing and modulating autoimmunity
WO2000049008A1 (en)	1999-02-20	2000-08-24	Astrazeneca Ab	Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin s
WO2000051998A1 (en)	1999-03-02	2000-09-08	Boehringer Ingelheim Pharmaceuticals, Inc.	Compounds useful as reversible inhibitors of cathepsin s
TW200404789A (en)	1999-03-15	2004-04-01	Axys Pharm Inc	Novel compounds and compositions as protease inhibitors
MXPA02001014A (es)	1999-07-30	2002-08-12	Boehringer Ingelheim Pharma	Nuevos compuestos derivados de succinato utiles como inhibidores de cisteina-proteasa.
EP1212302A1 (de)	1999-09-16	2002-06-12	Axys Pharmaceuticals, Inc.	Verbindungen und pharmazeutische zusammensetzungen als cathepsin-s-hemmer
AU1650501A (en)	1999-12-03	2001-06-12	Ono Pharmaceutical Co. Ltd.	1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
JP5049447B2 (ja) *	2000-08-14	2012-10-17	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	置換ピラゾール

2001
- 2001-08-10 JP JP2002519455A patent/JP5049447B2/ja not_active Expired - Lifetime
- 2001-08-10 AU AU8645401A patent/AU8645401A/xx active Pending
- 2001-08-10 WO PCT/US2001/025290 patent/WO2002014315A2/en not_active Ceased
- 2001-08-10 EP EP01965898A patent/EP1309593B1/de not_active Expired - Lifetime
- 2001-08-10 US US09/927,324 patent/US6953793B2/en not_active Expired - Lifetime
- 2001-08-10 CA CA2419552A patent/CA2419552C/en not_active Expired - Lifetime
- 2001-08-10 CZ CZ2003-429A patent/CZ307185B6/cs not_active IP Right Cessation
- 2001-08-10 HU HU0303108A patent/HU230538B1/hu not_active IP Right Cessation
- 2001-08-10 RU RU2003107016/04A patent/RU2317988C2/ru not_active Application Discontinuation
- 2001-08-10 PT PT01965898T patent/PT1309593E/pt unknown
- 2001-08-10 BR BRPI0113286A patent/BRPI0113286B8/pt not_active IP Right Cessation
- 2001-08-10 DE DE60118004T patent/DE60118004T2/de not_active Expired - Lifetime
- 2001-08-10 NZ NZ524191A patent/NZ524191A/en not_active IP Right Cessation
- 2001-08-10 AU AU2001286454A patent/AU2001286454B2/en not_active Expired
- 2001-08-10 PL PL360696A patent/PL213103B1/pl unknown
- 2001-08-10 ES ES01965898T patent/ES2261463T3/es not_active Expired - Lifetime
- 2001-08-10 MX MXPA03001422A patent/MXPA03001422A/es active IP Right Grant
- 2001-08-10 AT AT01965898T patent/ATE320427T1/de active
- 2001-08-10 DK DK01965898T patent/DK1309593T3/da active
- 2001-08-10 KR KR1020037002163A patent/KR100837193B1/ko not_active Expired - Lifetime
2005
- 2005-06-30 US US11/174,077 patent/US20050245576A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR100837193B1 (ko)	2008-06-13
RU2003107016A (ru)	2004-11-27
US20050245576A1 (en)	2005-11-03
BR0113286B1 (pt)	2013-04-16
US6953793B2 (en)	2005-10-11
RU2317988C2 (ru)	2008-02-27
CZ307185B6 (cs)	2018-03-07
EP1309593B1 (de)	2006-03-15
JP5049447B2 (ja)	2012-10-17
KR20030060876A (ko)	2003-07-16
MXPA03001422A (es)	2004-01-26
PT1309593E (pt)	2006-08-31
DK1309593T3 (da)	2006-07-17
EP1309593A2 (de)	2003-05-14
US20030078419A1 (en)	2003-04-24
HUP0303108A2 (hu)	2004-01-28
ES2261463T3 (es)	2006-11-16
CZ2003429A3 (cs)	2003-12-17
PL213103B1 (pl)	2013-01-31
AU8645401A (en)	2002-02-25
BR0113286A (pt)	2003-09-09
PL360696A1 (en)	2004-09-20
HU230538B1 (hu)	2016-11-28
WO2002014315A3 (en)	2002-06-13
CA2419552C (en)	2010-10-12
HK1055422A1 (en)	2004-01-09
DE60118004D1 (de)	2006-05-11
NZ524191A (en)	2004-11-26
WO2002014315A2 (en)	2002-02-21
AU2001286454B2 (en)	2006-09-14
DE60118004T2 (de)	2006-11-16
HUP0303108A3 (en)	2012-10-29
JP2004511440A (ja)	2004-04-15
BRPI0113286B8 (pt)	2021-05-25
CA2419552A1 (en)	2002-02-21

Legal Events

Date

Code

Title

Description

2007-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1309593

Country of ref document: EP

Publication	Publication Date	Title
DE60118004D1 (de)	2006-05-11	Substituierte pyrazole
DE60119124D1 (de)	2006-06-01	Substituierte pyrazole
WO2002014314A3 (en)	2002-06-06	Substituted pyrazoles
NO20030845D0 (no)	2003-02-24	Utvalgte fusjonerte pyrrolokarbazoler
BG66084B1 (bg)	2011-03-31	Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
NO991732L (no)	1999-06-04	Nye heterocyklylmetylsubstituerte pyrazolderivater
NO992400L (no)	1999-05-19	Nye substituerte pyrazolderivater
JO2481B1 (en)	2009-01-20	Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods
ATE532781T1 (de)	2011-11-15	5-(acylamino)indazol-derivate als kinase- inhibitoren
BG66080B1 (bg)	2011-03-31	Заместени тиоацетамиди
MY158159A (en)	2016-09-15	Novel fused pyrrolocarbazoles
MY149041A (en)	2013-07-15	Novel fused pyrrolocarbazoles
ATE302002T1 (de)	2005-09-15	Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
TR200402030T4 (tr)	2004-09-21	İkame edilen I-aminobutan-3-ol-türevleri
ATE247130T1 (de)	2003-08-15	Inhibitoren für den urokinaserezeptor
EP1436279B8 (de)	2008-10-29	Chemische verbindungen
CY1111290T1 (el)	2015-08-05	Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
BR0111221A (pt)	2003-03-18	Condensados glioxal-fenólicos com fluorescência intensificada
ECSP003336A (es)	2000-05-08	Acidos pirazolcarboxilicos sustituidos (lea 33524 - ec)